Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.
Blood
; 132(16): 1635-1646, 2018 10 18.
Article
en En
| MEDLINE
| ID: mdl-30108066
ABSTRACT
Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Traumatismos por Radiación
/
Guías de Práctica Clínica como Asunto
/
Órganos en Riesgo
/
Terapia de Protones
/
Linfoma
/
Neoplasias del Mediastino
Tipo de estudio:
Etiology_studies
/
Guideline
/
Prognostic_studies
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Blood
Año:
2018
Tipo del documento:
Article